# Vaccine Therapy for Patients With Stage IV Melanoma

> **NCT00052156** · PHASE3 · UNKNOWN · sponsor: **CancerVax Corporation** · enrollment: 670 (—)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** CancerVax vaccine (CANVAXIN)

## Key facts

- **NCT ID:** NCT00052156
- **Lead sponsor:** CancerVax Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 670 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052156, "Vaccine Therapy for Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00052156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*